However, it should be taken into account that especially in the context of immunodeficiency and high-replicative viral variants, viral evolution after therapy with CP and monoclonal antibodies, in particular bamlanivimab, has been reported17,41,42. This evidence concerns the gene CP and immunodeficiency disease.